Current strategies and future trends in immunosuppression after heart transplantation

Current Opinion in Organ Transplantation

Volumn 17, Issue 5, 2012, Pages 540-545

  Aliabadi, Arezu ^a   Cochrane, Adam B ^b   Zuckermann, Andreas O ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Inova Fair Hospital   (United States)

Author keywords

complications; heart transplantation; immunosuppression; individualization

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

AGE DISTRIBUTION; ANEMIA; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; GINGIVA HYPERPLASIA; GRAFT REJECTION; HEART TRANSPLANTATION; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LEUKOPENIA; LIPID BLOOD LEVEL; LYMPHOMA; MYCOSIS; NAUSEA; PERICARDIAL EFFUSION; POSTOPERATIVE COMPLICATION; REVIEW; SIDE EFFECT; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL;

GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; PROSPECTIVE STUDIES;

EID: 84866394262     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328358000c     Document Type: Review

References (49)

1. Stehlik J, Edwards LB, Kucheryavaya AY, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult heart transplant report-2011. J Heart Lung Transplant 2011; 30:1078-1079.
2. Carlsen J, Johansen M, Boesgaard S, et al. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. J Heart Lung Transplant 2005; 24:296-302. (Pubitemid 40312054)
3. Carrier M, Leblanc M, Perrault P, et al. Basiliximab and rabbit antithymocyte globulin for prophylaxis of acute rejection after heart transplantation: a noninferiority trial. J Heart Lung Transplant 2007; 26:258-263. (Pubitemid 46341886)
4. Mattei M, Redonnet M, Gandjbakhch I, et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus antithymocyte globulin as induction therapy. J Heart Lung Transplant 2007; 26:693-699. (Pubitemid 47001715)
5. Delgado DH, Miriuka SG, Cusimano RJ, et al. Use of basiliximab and cyclosporine in heart transplant patients with preoperative renal dysfunction. J Heart Lung Transplant 2005; 24:166-169. (Pubitemid 40215592)
6. Flaman F, Zieroth S, Rao V, et al. Basiliximab versus rabbit antithymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant 2006; 25:1358-1362. (Pubitemid 44692505)
7. Chou N, Wang S, Chen Y, et al. Induction immunosuppression with basiliximab in heart transplantation. Transpl Proc 2008; 40:2623-2625.
8. Teuteberg J, Shullo M, Zomak R, et al. Alemtuzumab induction prior cardiac transplantation with lower intensity immunosuppression: one-year data. Am J Transplant 2010; 10:382-388.
9. Emin A, Rogers C, Thekkudan J, et al. Antithymocyte globulin therapy for adult heart transplantation: a UK national study. J Heart Lung Transplant 2011; 30:770-777.
10. Gajarski R, Blume E, Urschel S, et al. Infection and malignancy after pediatric transplantation: the role of induction therapy. J Heart Lung Transplant 2011; 30:299-308.
11. Dayton J, Richmond M, Weintraub R, et al. Role of immunosuppression regimen in posttransplant lymphoproliferative disorder in pediatric transplant patients. J Heart Lung Transplant 2011; 30:420-425.
12. Crespo-Leiro M, Alonso-Pulpon L, Arizon J, et al. Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish postheart transplant tumour registry. J Heart Lung Transplant 2007; 26:1105-1109. (Pubitemid 350088521)
13. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29:914-956.
14. Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients: a large European trial. Am J Transplant 2006; 6:1387-1397. (Pubitemid 44030321)
15. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377-1386. (Pubitemid 44030320)
16. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18:336-345. (Pubitemid 29205269)
17. Reichart B, Meiser B, Vigano M, et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results-European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998; 17:775-781. (Pubitemid 28396987)
18. Lehmkuhl HB, Arizon J, Vigano M, et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009; 88:115-122.
19. Kobashigawa J, Pauly D, Kfoury A, et al. Multicenter randomized trial of everolimus vs. mycophenolate mofetil in heart transplantation: final 24 month analysis of efficacy and safety. J Heart Lung Transplant 2012; 31 (Suppl):S73-S74.
20. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110:2694-2700. (Pubitemid 39453021)
21. Pawelec G. Immunosenescence: impact in the young as well as the old? Mech Ageing Dev 1999; 108:1-7. (Pubitemid 29210235)
22. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000; 31:578-585. (Pubitemid 32289594)
23. Bradley BA. Rejection and recipient age. Transpl Immunol 2002; 10:125-132.
24. Baran D, Zucker M, Arroyo L, et al. A prospective, randomized trial of singledrug versus dual-drug immunosuppression in heart transplantation: the Tacrolimus in Combination, Tacrolimus Alone Compared (TICTAC) trial. Circ Heart Fail 2011; 4:129-137.
25. Rosenberg PB, Vriesendorp AE, Drazner MH, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 2005; 24:1327-1331. (Pubitemid 41247817)
26. Cantarovich M, Giannetti N, Barkun J, et al. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 2004; 78:779-781. (Pubitemid 39244749)
27. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6:514-522. (Pubitemid 43382137)
28. Webster AC, Lee VWS, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus, and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81:1234-1248.
29. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562.
30. Meiser B, Reichart B, Adamidis I, et al. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 2005; 5 (4 Pt 1):827-831. (Pubitemid 40461294)
31. Gonzá lez-V́lchez F, de Prada JA, Exposito V, et al. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant 2008; 27:1135-1141.
32. Kobashigawa, Mehra M, West L, et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant 2009; 28:213-225.
33. Gullestad L, Iversen M, Mortensen SA, et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010; 89:864-872.
34. Potena L, Bianchi IG, Magnani G, et al. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study. Transplantation 2010; 89:263-265.
35. Groetzner J, Kaczmarek I, Schulz U, et al., VENINAHTx-Investigators. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 2009; 87:726-733.
36. Engelen MA, Amler S, Welp H, et al. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years. Transplantation 2011; 91:1159-1165.
37. Zuckermann A, Keogh A, Crespo-Leiro M, et al. randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency. Am J Transplant. doi: 10.1111/j.1600-6143.2012.04131.x. [Epub ahead of print].
38. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007; 67:1167-1198. (Pubitemid 46871026)
39. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4:222-230. (Pubitemid 38248525)
40. Patel J, Kobashigawa JA. Minimization of immunosuppression: transplant immunology. Transpl Immunol 2008; 20:48-54.
41. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006; 82:663-668. (Pubitemid 44395237)
42. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006; 6:150-160. (Pubitemid 43382213)
43. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17:581-589.
44. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimustreated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18:446-449. (Pubitemid 39077081)
45. Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10:1385-1393.
46. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007; 13:433-442. (Pubitemid 47570021)
47. Albanell J, Dalmases A, Rovira A, Rojo F. mTOR signalling in human cancer. Clin Transl Oncol 2007; 9:484-493.
48. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80:883-889. (Pubitemid 41552882)
49. Manito N, Delgado JF, Crespo-Leiro MG, et al. Clinical recommendations for the use of everolimus in heart transplantation. Transplant Rev (Orlando) 2010; 24:129-142.